stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) Return on assets
Fortrea Holdings Inc.'s return on assets over the twelve months to 30 September 2026 was −2.51%, up 28.8 percentage points from fiscal 2025 (−31.3%). Over the past ten years it has ranged from −31.3% (fiscal 2025) to 8.68% (fiscal 2022) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −46.1% and above the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −31.3% | (23.03) |
| FY2024 | −8.30% | (7.72) |
| FY2023 | −0.58% | (9.26) |
| FY2022 | 8.68% | 8.68 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| HRMY Harmony Biosciences Holdings, Inc. compare | 13.3% |
| TRAX First Tracks Biotherapeutics, Inc. compare | 0.00% |
| FTRE Fortrea Holdings Inc. | −2.51% |
| SRPT Sarepta Therapeutics, Inc. compare | −3.44% |
| VIR Vir Biotechnology, Inc. compare | −17.3% |
| ZYME Zymeworks Inc. compare | −37.3% |
| IMNM Immunome, Inc. compare | −59.0% |
| REPL Replimune Group, Inc. compare | −71.0% |
| BHVN Biohaven Ltd. compare | −161.3% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)